| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Evanston Northwestern Healthcare Research Institute, Northwestern University, Evanston, IL
Requests for reprints: Ruth Lupu, Evanston Northwestern Healthcare Research Institute, 1001 University Place, Evanston, IL 60201. Phone: (847) 570-7672; Fax: (847) 570-8025. E-mail: rlupu{at}enh.org
Resistance of breast carcinomas to hormonal therapy is a clinical obstacle for the treatment of breast cancer. The molecular mechanisms and the factors involved in the progression of tumors from an estrogen (E2)-dependent to an E2-independent phenotype are not entirely understood. Heregulin (HRG) is a pleiotropic growth factor that binds to the erbB family of receptors, which are correlated with breast cancer progression and an aggressive phenotype in the breast carcinomas overexpressing the receptors. Previous studies in transgenic mice have shown that HRG is sufficient to induce mammary gland transformation and proliferation in the presence of hormonal stimulation. However, these studies did not address the important issue of the E2 independence that is part of the progression of breast cancer. In this study, we investigated the role of HRG in E2 independence. We were able to determine that HRG up-regulation was sufficient for the development of mammary tumors in the absence of E2 stimulation, a situation that mimics the progression of the human disease. We demonstrated that in ovariectomized nude mice, HRG induced E2 independence and antiestrogen resistance and promoted metastasis and preneoplastic transformation of the adjacent mouse mammary tissue. We show that one of the mechanisms by which HRG achieves the aggressive phenotype may be mediated via an increase in activated mitogen-activated protein kinase, an increase in a matrix-degrading enzyme, MMP-9, and the overexpression of vascular endothelial growth factors. The up-regulation of these genes occurred in the absence of any additional stimulation, in an autocrine manner. Our data provide new insights into the mechanisms of breast cancer progression in vivo, and reinforce the important role that HRG plays in this process.
This article has been cited by other articles:
|
|
 |
|
  Z. Qu, S. Van Ginkel, A. M. Roy, L. Westbrook, M. Nasrin, Y. Maxuitenko, A. R. Frost, D. Carey, W. Wang, R. Li, et al. Vascular Endothelial Growth Factor Reduces Tamoxifen Efficacy and Promotes Metastatic Colonization and Desmoplasia in Breast Tumors Cancer Res., August 1, 2008; 68(15): 6232 - 6240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. T. Lee-Hoeflich, L. Crocker, E. Yao, T. Pham, X. Munroe, K. P. Hoeflich, M. X. Sliwkowski, and H. M. Stern A Central Role for HER3 in HER2-Amplified Breast Cancer: Implications for Targeted Therapy Cancer Res., July 15, 2008; 68(14): 5878 - 5887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Montero, R. Rodriguez-Barrueco, A. Ocana, E. Diaz-Rodriguez, A. Esparis-Ogando, and A. Pandiella Neuregulins and Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3237 - 3241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Westbrook, M. Manuvakhova, F. G. Kern, N. R. Estes II, H. N. Ramanathan, and J. V. Thottassery Cks1 Regulates cdk1 Expression: A Novel Role during Mitotic Entry in Breast Cancer Cells Cancer Res., December 1, 2007; 67(23): 11393 - 11401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. de Alava, A. Ocana, M. Abad, J. C. Montero, A. Esparis-Ogando, C. A. Rodriguez, A. P. Otero, T. Hernandez, J. J. Cruz, and A. Pandiella Neuregulin Expression Modulates Clinical Response to Trastuzumab in Patients With Metastatic Breast Cancer J. Clin. Oncol., July 1, 2007; 25(19): 2656 - 2663. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Menendez, I. Mehmi, and R. Lupu Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression J. Clin. Oncol., August 10, 2006; 24(23): 3735 - 3746. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Arteaga Can Trastuzumab Be Effective Against Tumors With Low HER2/Neu (ErbB2) Receptors? J. Clin. Oncol., August 10, 2006; 24(23): 3722 - 3725. [Full Text] [PDF]
|
|
|
|
 |
|
 D. Meijer, T. van Agthoven, P. T. Bosma, K. Nooter, and L. C.J. Dorssers Functional Screen for Genes Responsible for Tamoxifen Resistance in Human Breast Cancer Cells Mol. Cancer Res., June 1, 2006; 4(6): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Smirnov, B. W. Foulk, G. V. Doyle, M. C. Connelly, L. W.M.M. Terstappen, and S. M. O'Hara Global gene expression profiling of circulating endothelial cells in patients with metastatic carcinomas. Cancer Res., March 15, 2006; 66(6): 2918 - 2922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Yang, Y. Liu, M. A. Lemmon, and M. G. Kazanietz Essential Role for Rac in Heregulin {beta}1 Mitogenic Signaling: a Mechanism That Involves Epidermal Growth Factor Receptor and Is Independent of ErbB4 Mol. Cell. Biol., February 1, 2006; 26(3): 831 - 842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Breuleux, F. Schoumacher, D. Rehn, W. Kung, H. Mueller, and U. Eppenberger Heregulins Implicated in Cellular Functions Other Than Receptor Activation Mol. Cancer Res., January 1, 2006; 4(1): 27 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yuste, J. C. Montero, A. Esparis-Ogando, and A. Pandiella Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin Cancer Res., August 1, 2005; 65(15): 6801 - 6810. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R I Nicholson, C Staka, F Boyns, I R Hutcheson, and J M W Gee Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy Endocr. Relat. Cancer, December 1, 2004; 11(4): 623 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Li, S. Ahmed, and J. A. Loeb Development of an Autocrine Neuregulin Signaling Loop with Malignant Transformation of Human Breast Epithelial Cells Cancer Res., October 1, 2004; 64(19): 7078 - 7085. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Tangkeangsirisin and G. Serrero PC cell-derived growth factor (PCDGF/GP88, progranulin) stimulates migration, invasiveness and VEGF expression in breast cancer cells Carcinogenesis, September 1, 2004; 25(9): 1587 - 1592. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
